Merck Receives Complete Response Letter From US FDA for Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)Business Wire • 03/29/21
Merck to Hold First-Quarter 2021 Sales and Earnings Conference Call on April 29Business Wire • 03/29/21
Is Merck Stock A Buy As It Teams Up To Produce J&J's Covid Vaccine?Investors Business Daily • 03/26/21
FDA Approves Merck's KEYTRUDA® (pembrolizumab) Plus Platinum- and Fluoropyrimidine-Based Chemotherapy for Treatment of Certain Patients With Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction (GEJ) CarcinomaBusiness Wire • 03/23/21
Merck' Keytruda Plus Eisai's Lenvima Cuts Risk Of Death By 38% In Endometrial Cancer Trial Compared To ChemoBenzinga • 03/19/21
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Significantly Improved Progression-Free Survival and Overall Survival Versus Chemotherapy in Patients With Advanced Endometrial Cancer Following Prior Platinum-Based Chemotherapy in Phase 3 StudyBusiness Wire • 03/19/21
Merck Announces Filing of Form 10 Registration Statement in Connection with Planned Spinoff of Organon & Co.Business Wire • 03/17/21
Amathus Therapeutics, Merck In Agreement For Neurodegenerative Disease-Targeted TherapiesBenzinga • 03/17/21